GLPwatch
Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.
Endocr Metab Immune Disord Drug Targets · 2023
Last updated 2026-05-28Tirzepatide, also known as Mounjaro, is a medication approved by the FDA to help improve blood sugar control in adults with type 2 diabetes when combined with diet and exercise. It works by activating two hormones, GLP-1 and GIP, which help regulate blood sugar levels. The medication is given as an injection.
AI summary of the abstract below.
| Journal | Endocr Metab Immune Disord Drug Targets, 2023 |
|---|---|
| Citations | 8 |
| Relative citation ratio | 0.89 |
| NIH percentile | 46 |
| Molecules | tirzepatide |
| Conditions studied | Type 2 Diabetes |
Abstract
Tirzepatide (mounjaro) is a derivative of the human glucose-dependent insulinotropic polypeptide (GIP) hormone with a position-20 being modified with 1,20- eicosanedioic acid via a chemical linker. It acts as a glucagon-like peptide-1 (GLP-1) receptor and GIP receptor agonist. It has recently been approved by FDA as an adjunct therapy to exercise and diet to improve glycemic control in patients with type II diabetes mellitus (T2DM). It represents a new transforming paradigm in the management of T2DM. This mini-review will shed light on its different pharmacokinetic and pharmacodynamic aspects.
Verbatim abstract via PubMed 36200219 ↗
Related research
- Tirzepatide Once Weekly for the Treatment of Obesity.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial.
- Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis.
- Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity.
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
- Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial.